Mankind Pharma Limited

MANKIND

INE634S01028

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 05:19:42 11/07/2025 pm IST			5-day change	1st Jan Change
2,578.30 ^INR	+1.35%		+5.69%	-10.49%

11/07	Jefferies Adjusts Mankind Pharma's Price Target to INR3,000 From INR2,870, Keeps at Buy	MT
30/06	India's Torrent Pharma to acquire controlling stake in JB Chem and Pharma	RE

Mankind Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2025

Published on 21/05/2025 at 18:19

Mankind Pharma Limited reported earnings results for the full year ended March 31, 2025. For the full year, the company reported sales was INR 122,074.4 million compared to INR 102,604.4 million a year ago. Revenue was INR 127,442.3 million compared to INR 105,406.6 million a year ago.

Net income was INR 19,909.6 million compared to INR 19,129 million a year ago. Basic earnings per share from continuing operations was INR 49.17 compared to INR 47.73 a year ago. Diluted earnings per share from continuing operations was INR 49.08 compared to INR 47.66 a year ago.

Basic earnings per share was INR 49.28 compared to INR 47.75 a year ago. Diluted earnings per share was INR 49.2 compared to INR 47.68 a year ago.

Latest news about Mankind Pharma Limited

Jefferies Adjusts Mankind Pharma's Price Target to INR3,000 From INR2,870, Keeps at Buy	11/07	MT
India's Torrent Pharma to acquire controlling stake in JB Chem and Pharma	30/06	RE
Lilly to launch Mounjaro pen in India as Novo rivalry heats up in mega market	27/06	RE
Lilly to launch Mounjaro pen in India as Novo rivalry heats up in mega market	26/06	RE
Mankind Pharma Incorporates Not-for-Profit Subsidiary	03/06	MT
Maneane Pharma Limited Announces Intimation of Incorporation of A Wholly Owned Subsidiary Company	02/06	CI
Mankind Pharma Limited, Q4 2025 Earnings Call, May 21, 2025	27/05
Jefferies Adjusts Mankind Pharma's Price Target to INR2,870 From INR3,300, Keeps at Buy	23/05	MT
Mankind Pharma to Incorporate Wholly Owned Subsidiary in Sri Lanka	22/05	MT
India's Mankind Pharma beats profit estimates on demand for drugs to treat chronic illnesses	21/05	RE
Mankind Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2025	21/05	CI
Mankind Pharma Q4 Consol Net Profit 4.21 Billion Rupees IBES Est. 3.60 Billion Rupees	21/05	RE
Mankind Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025	21/05	CI
Mankind Pharma Says Tax Authority Raises Additional Tax Demand Of 763 Mln Rupees	14/05	RE
Mankind Pharma Says Tax Authority Raised Additional Tax Demand Of 1.28 Billion Rupees	09/05	RE
Mankind Pharma Gets Board Nod to Form Two Subsidiaries	15/04	MT
Mankind Pharma To Incorporate Wholly Owned Subsidiary In Russia	14/04	RE
Mankind Pharma Limited Announces Incorporation of Wholly Owned Subsidiary, Directly or Indirectly, in Russia and Wholly Owned Subsidiary Under Section 8 of the Companies Act, 2013	14/04	CI
Mankind Pharma Limited Announces Issuance of Debt Securities for the Half Year Ended March 31, 2025	11/04	CI
Mankind Pharma Says NCLT Approves Amalgamation Of BSV Pharma With Bharat Serums And Vaccines	28/03	RE
Mankind Pharma Says IT Authority Raises Additional Tax Demand Of 1.83 Billion Rupees	28/03	RE
CARE Withdraws Ratings on Mankind Pharma's Debt Instruments	26/03	MT
Certain Equity Shares of Mankind Pharma Limited are subject to a Lock-Up Agreement Ending on 20-MAR-2025.	20/03	CI
Mankind Pharma Limited Receives Order Issued by Deputy Commissioner State Tax, Trimurti Nagar, Nagpur	01/03	CI
Mankind Pharma Says Income Tax Department Raises Additional Tax Demand Of 1.12 Billion Rupees	28/02	RE

Chart Mankind Pharma Limited

Duration

Period

MANKIND: Dynamic Chart

Company Profile

Mankind Pharma Limited is an India-based pharmaceutical company. It is engaged in developing, manufacturing, and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It offers healthcare solutions for a range of healthcare needs with a portfolio that includes anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/ central nervous system, vitamins, minerals and nutrients and respiratory therapies. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others. Its branded product portfolio spans womenâs health, fertility and critical care, with several brands in their respective therapy areas. Its subsidiaries include Lifestar Pharma Private Limited, Magnet Labs Private Limited, Jaspack Industries Private Limited, and others.

Employees

19,540

Sector

Pharmaceuticals

Calendar

30/07 - Q1 2026 Earnings Release (Projected)

More about the company